The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-15), VBI Vaccines's share price is $0.6369. VBI Vaccines's Book Value per Share for the quarter that ended in Dec. 2023 was $0.32. Hence, VBI Vaccines's PB Ratio of today is 2.02.
The historical rank and industry rank for VBI Vaccines's PB Ratio or its related term are showing as below:
VBIV'
s PB Ratio Range Over the Past 10 Years
Min: 0.42 Med: 2.19 Max: 11.24
Current: 1.99
During the past 13 years, VBI Vaccines's highest PB Ratio was 11.24. The lowest was 0.42. And the median was 2.19.
VBIV's PB Ratio is ranked better than 59.24% of 1320
companies
in the Biotechnology industry
Industry Median: 2.52
vs VBIV: 1.99
During the past 12 months, VBI Vaccines's average Book Value Per Share Growth Rate was -95.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -75.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -51.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -48.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of VBI Vaccines was 234.10% per year. The lowest was -75.30% per year. And the median was -19.70% per year.
Back to Basics: PB Ratio
VBI Vaccines PB Ratio Historical Data
The historical data trend for VBI Vaccines's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, VBI Vaccines's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VBI Vaccines's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VBI Vaccines's PB Ratio distribution charts can be found below:
* The bar in red indicates where VBI Vaccines's PB Ratio falls into.
VBI Vaccines PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
VBI Vaccines's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
VBI Vaccines PB Ratio Related Terms
Thank you for viewing the detailed overview of VBI Vaccines's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
VBI Vaccines Inc is a US-based commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VBIV has been successfully added to your 